The only other gene therapies to have made it to market so far are uniQure’s Glybera’s (alipogene tiparvovec), and GSK’s Strimvelis, but both have only gained EU approval. Glybera is a case ...

So far only three commercial gene therapies have been approved across the globe. One of which, Glybera, was developed for the ultra-rare inherited disease familial lipoprotein lipase deficiency ...